Jon Markman

Jon Markman

Jon Markman is the editor of Trader’s Advantage, a daily trading service that leverages his unique swing trading principles and aims to capture profits of 7% to 15% — and often much more with his options trades — in less than 90 days. By combining technical analysis with underlying fundamentals, Jon recommends beaten down stocks on the brink of reversal and powerful momentum stocks breaking out to new highs.

In CounterPoint Options Jon helps options traders lock in consistent profits from the volatility that rocks the market. At its heart is a proprietary trading system, Magnitude, that pinpoints indexes or sectors that have reached a critical inflection point — then translates that signal into profitable trades.

CounterPoint Options keeps volatility options trading very simple, focusing on the most popular, highly traded exchange-traded funds (ETFs) that are headed for a key reversal. Magnitude scans the market and allows subscribers to take advantage of these very liquid trading opportunities.

When CounterPoint Options first launched, it was focused solely on trading the VIX, commonly known as the “fear index.” When traders start buying up put options as “portfolio insurance,” the VIX spikes — a phenomenon that we’ll either trade directly, or use to inform our ETF trades on specific slices of the market. Our agile (and highly lucrative) strategy lets us turn volatility into profits… just like professional traders and hedge funds have been doing for years.

CounterPoint Options helps individual traders make steady, consistent profits from a very methodical approach to growing your portfolio in the midst of a turbulent market.

A pioneer in the development of stock-rating systems and screening software, Jon Markman is co-inventor on two Microsoft patents and author of the best-selling books Swing Trading and Online Investing. He was portfolio manager and senior investment strategist at a multi-strategy hedge fund from 2002 to 2005; managing editor and columnist at CNBC on MSN Money from 1997 to 2002; and an editor, investment columnist and investigative reporter at the Los Angeles Times from 1984 to 1997.

Jon won a Gerald Loeb Award for Distinguished Financial Journalism for his columns explaining market chicanery in 2002; Society of Professional Journalists awards for his 2001 reporting on Enron and the post-Sept. 11-investment environment; and was a news editor on the Los Angeles Times staff that won Pulitzer Prizes for spot-news reporting in 1992 and 1994.

A graduate of Duke University and the Columbia University Graduate School of Journalism, Jon speaks frequently on investment topics at conferences nationwide, as well as on TV and radio.

Recent Articles

MLP Enterprise GP (EPE) Offers Big Dividend and Big Stock Gains

Energy master limited partnerships or MLPs have quietly carved out a role as the leading industry in the stock market. That’s because these high yield dividend stocks deliver big dividends and many have seen share prices gain as well. Enterprise GP Holdings (EPE) is just one such MLP stock to buy.

Valeant (VRX) Benefits from Merger with Biovail (BVF)

The merger announcement that Valeant Pharmaceuticals (VRX) would combine with troubled Canadian biotech firm Biovail (BVF) was one of largest of the past several months. The new company will retain the Valeant name, but will be controlled by Biovail shareholders, 50.5% to 49.5%.

Viacom Outpaces Rivals News Corp, Disney, Time Warner (VIA, NWS, DIS, TWX, DWA)

Viacom (VIA), the New York based broadcasting company, is among the biggest stock market surprises this year . Global media conglomerate Viacom is retaking its place at the forefront of the entertainment industry, with VIA stock up 15% in this challenging year.

Stocks to Buy – Health Care Investment Immucor (BLUD)

When investors think about the best stocks to buy, let's take a quick look at investment Immucor Inc. (BLUD), one of my recommended stocks that specializes in blood testing. Immucor has done very well so far this month, with BLUD stock rising on higher than normal volume.

Stocks to Buy – Tech Investment Kulicke and Soffa (KLIC)

Tech stock investors looking for the best stocks to buy should consider Kulicke and Soffa (KLIC). This technology investment makes chip assembly equipment. My recent recommendation was for buying this stock via July $7.50 call options, and they are definitely clicking so far -- up 38% so far, with more to go.